Taysha Gene Therapies (TSHA) Accumulated Expenses (2019 - 2026)

Taysha Gene Therapies (TSHA) has 8 years of Accumulated Expenses data on file, last reported at $4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 93.27% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (up 93.27% YoY), and the FY2025 full-year result was $3.6 million, up 109.51% from the prior year.
• Accumulated Expenses climbed to $4.9 million in Q1 2026, from $3.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $19.0 million in Q2 2022 to a low of $1.6 million in Q1 2024.
• A 5-year average of $8.8 million and a median of $5.7 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses plunged 90.51% in 2024 and soared 365.02% in 2025, its largest moves.
• Tracing TSHA's Accumulated Expenses over 5 years: stood at $18.3 million in 2022, then slumped by 81.04% to $3.5 million in 2023, then slumped by 50.56% to $1.7 million in 2024, then soared by 109.51% to $3.6 million in 2025, then jumped by 35.09% to $4.9 million in 2026.
• Business Quant data shows TSHA's Accumulated Expenses at $4.9 million in Q1 2026, $3.6 million in Q4 2025, and $5.3 million in Q3 2025.